The evolution of an inflammatory response

Surgical Infections

Volumn 10, Issue 5, 2009, Pages 419-425

  Lowry, Stephen F ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; GLUCOCORTICOID;

CIRCADIAN RHYTHM; COMORBIDITY; CYTOKINE PRODUCTION; ENVIRONMENTAL FACTOR; HORMONE RELEASE; HUMAN; IATROGENIC DISEASE; IMMUNE SYSTEM; INFECTION; INFLAMMATION; INJURY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEPSIS; SEX DIFFERENCE; STEROID THERAPY;

AGED; FEMALE; HUMANS; INFLAMMATION; MALE; WOUNDS AND INJURIES;

EID: 72449207105     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2009.018     Document Type: Review

References (82)

1. Shires GT, Fisher O, Murphy P, et al. Recombinant activated protein C induces dose-dependent changes in inflammatory mediators, tissue damage, and apoptosis in in vivo rat model of sepsis. Surg Infect 2007;8:377-386.
2. Shires GT. Response to ''Delayed fluid resuscitation in hemorrhagic shock induces proinflammatory cytokine response.'' Ann Emerg Med 2007;50:354.
3. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-3670.
4. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985;316:552-554.
5. Tracey KJ, Lowry SF, Beutler B, et al. Cachectin=tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential. J Exp Med 1986;164:1368-1373.
6. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-474.
7. Tracey KJ, Wei H, Manogue KR, et al. Cachectin=tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 1988;167:1211-1227.
8. Hesse DG, Tracey KJ, Fong Y, et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988;166:147-153.
9. Marano MA, Fong Y, Moldawer LL, et al. Serum cachectin=tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet 1990;170:32-38.
10. Barber AE, Coyle SM, Marano MA, et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993;150:1999-2006.
11. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988;318:1481-1486.
12. Van Der Poll T, Coyle SM, Barbosa K, et al. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996;97:713-719.
13. Dinarello CA, Roubenoff R. George Clowes' classic paper and the search for ''muscle proteolysis factor.'' Nutrition 1996;12:67-68.
14. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin=TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-664.
15. Fischer E, MaranoMA,Van Zee KJ, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992;89:1551-1557.
16. Van Der Poll T, Coyle SM, Levi M, et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood 1997;89:3727-3734.
17. Van Der Poll T, Jansen PM, van Zee KJ, et al. Tumor necrosis factor-alpha induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. Blood 1996;88:922-927.
18. van Zee KJ, Kohno T, Fischer E, et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992;89:4845-4859.
19. van Zee KJ, Moldawer LL, Oldenburg HS, et al. Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J Immunol 1996; 156:2221-2230.
20. Opal SM, Cross AS. Clinical trials for severe sepsis: Past failures, and future hopes. Infect Dis Clin North Am 1999;13:285-297.
21. Eichacker PQ, Parent C, Kalil A, et al. Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002;166:1197-1205.
22. Van Der Poll T, Levi M, Dentener M, et al. Epinephrine exerts anticoagulant effects during human endotoxemia. J Exp Med 1997;185:1143-1148.
23. Boermeester MA, van Leeuwen PA, Coyle SM, et al. Interleukin- 1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. Arch Surg 1995;130:739-748.
24. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
25. Kalil AC, Coyle SM, Um JY, et al. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 2004;21:222-229.
26. Barie PS, Hydo LJ, Shou J, Eachempati SR. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis. Surg Infect 2006; 7(Suppl 2):S77-S80.
27. Barie PS, Williams MD, McCollam JS, et al. Benefit=risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 2004;188:212-220.
28. Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-658.
29. Annane D, Briegel J, Sprung CL. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003;348:2157-2159.
30. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-124.
31. Lowry SF, Calvano SE. Challenges for modeling and interpreting the complex biology of severe injury and inflammation. J Leukocyte Biol 2008;83:553-557.
32. Rixen D, Siegel JH, Abu-Salih A, et al. Physiologic state severity classification as an indicator of posttrauma cytokine response. Shock 1995;4:27-38.
33. Rixen D, Siegel JH, Friedman HP. ''Sepsis=SIRS,'' physiologic classification, severity stratification, relation to cytokine elaboration and outcome prediction in posttrauma critical illness. J Trauma 1996;41:581-598.
34. Siegel JH, Vary TC, Rivkind A, et al. Abnormal metabolic control in the septic multiple organ failure syndrome: Pharmacotherapy for altered fuel control mechanisms. Prog Clin Biol Res 1989;308:535-543.
35. Tschoeke SK, Hellmuth M, Hostmann A, et al. The early second hit in trauma management augments the proinflammatory immune response to multiple injuries. J Trauma 2007;62:1396-1403.
36. Chen CJ, Kono H, Golenbock D, et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007;13:851-856.
37. Barton GM. A calculated response: Control of inflammation by the innate immune system. J Clin Invest 2008;118:413-420.
38. Nathan C. Points of control in inflammation. Nature 2002;420:846-852.
39. Fuller PM, Lu J, Saper CB. Differential rescue of light- and food-entrainable circadian rhythms. Science 2008;320:1074-1077.
40. Martino TA, Oudit GY, Herzenberg AM, et al. Circadian rhythm disorganization produces profound cardiovascular and renal disease in hamsters. Am J Physiol Regul Integr Comp Physiol 2008;294:R1675-R1683.
41. Kohsaka A, Bass J. A sense of time: How molecular clocks organize metabolism. Trends Endocrinol Metab 2007;18: 4-11.
42. Carlson DE, Chiu WC. The absence of circadian cues during recovery from sepsis modifies pituitary-adrenocortical function and impairs survival. Shock 2008;29:127-132.
43. Okada K, Yano M, Doki Y, et al. Injection of LPS causes transient suppression of biological clock genes in rats. J Surg Res 2008;145:5-12.
44. Cavadini G, Petrzilka S, Kohler P, et al. TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc Natl Acad Sci USA 2007;104:12843-12848.
45. Bonnemeier H, Richardt G, Potratz J, et al. Circadian profile of cardiac autonomic nervous modulation in healthy subjects: Differing effects of aging and gender on heart rate variability. J Cardiovasc Electrophysiol 2003;14:791-799.
46. Annane D, Trabold F, Sharshar T, et al. Inappropriate sympathetic activation at onset of septic shock: A spectral analysis approach. Am J Respir Crit Care Med 1999;160:458-465.
47. Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007;117:289-296.
48. Steptoe A, Wardle J, Marmot M. Positive affect and healthrelated neuroendocrine, cardiovascular, and inflammatory processes. Proc Natl Acad Sci USA 2005;102:6508-6512.
49. Lowry SF. Host metabolic response to injury. In: Gallin J, Fauci A, eds. Advances in Host Defense Mechanisms. New York. Raven Press. 1986: pp 169-190.
50. Van Den Berghe G, de Zegher F, Bouillon R. Clinical review 95: Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 1998;83:1827-1834.
51. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310.
52. Dhainaut JF, Claessens YE, Janes J, Nelson DR. Underlying disorders and their impact on the host response to infection. Clin Infect Dis 2005;41(Suppl 7):S481-S489.
53. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol 2007;211:144-156.
54. Opal SM, Girard TD, Ely EW. The immunopathogenesis of sepsis in elderly patients. Clin Infect Dis 2005;41 (Suppl 7):S504-S512.
55. Yende S, Tuomanen EI, Wunderink R, et al. Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. Am J Respir Crit Care Med 2005;172: 1440-1446.
56. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: Results from the Health ABC study. Circulation 2003;108:2317-2322. (Pubitemid 37413536)
57. Krabbe KS, Bruunsgaard H, Hansen CM, et al. Ageing is associated with a prolonged fever response in human endotoxemia. Clin Diagn Lab Immunol 2001;8:333-338.
58. Bruunsgaard H, Skinhoj P, Qvist J, Pedersen BK. Elderly humans show prolonged in vivo inflammatory activity during pneumococcal infections. J Infect Dis 1999;180:551-554.
59. Magnotti LJ, Fischer PE, Zarzaur BL, et al. Impact of gender on outcomes after blunt injury: A definitive analysis of more than 36,000 trauma patients. J Am Coll Surg 2008;206:984-991.
60. Sperry JL, Nathens AB, Frankel HL, et al. Characterization of the gender dimorphism after injury and hemorrhagic shock: Are hormonal differences responsible? Crit Care Med 2008;36:1838-1845.
61. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988;318:727-732.
62. Wurfel MM, Park WY, Radella F, et al. Identification of high and low responders to lipopolysaccharide in normal subjects: An unbiased approach to identify modulators of innate immunity. J Immunol 2005;175:2570-2578.
63. de Craen AJ, Posthuma D, Remarque EJ, et al. Heritability estimates of innate immunity: An extended twin study. Genes Immun 2005;6:167-170.
64. Buchman TG. Nonlinear dynamics, complex systems, and the pathobiology of critical illness. Curr Opin Crit Care 2004;10:378-382.
65. Morris JA Jr, Norris PR, Ozdas A, et al. Reduced heart rate variability: An indicator of cardiac uncoupling and diminished physiologic reserve in 1,425 trauma patients. J Trauma 2006;60:1165-1173. (Pubitemid 43916573)
66. Norris PR, Morris JA Jr, Ozdas A, et al. Heart rate variability predicts trauma patient outcome as early as 12 h: Implications for military and civilian triage. J Surg Res 2005;129: 122-128.
67. Norris PR, Ozdas A, Cao H, et al. Cardiac uncoupling and heart rate variability stratify ICU patients by mortality: A study of 2088 trauma patients. Ann Surg 2006;243:804-812. (Pubitemid 44297488)
68. Godin PJ, Buchman TG. Uncoupling of biological oscillators: A complementary hypothesis concerning the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 1996;24:1107-1116.
69. Van Den Berghe GH. The neuroendocrine stress response and modern intensive care: The concept revisited. Burns 1999;25:7-16.
70. Morris JA Jr, Norris PR, Waitman LR, et al. Adrenal insufficiency, heart rate variability, and complex biologic systems: A study of 1,871 critically ill trauma patients. J Am Coll Surg 2007;204:885-892.
71. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-1377.
72. Rivers EP, Kruse JA, Jacobsen G, et al. The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock. Crit Care Med 2007;35:2016-2024.
73. Lang K, Boldt J, Suttner S, Haisch G. Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery. Anesth Analg 2001;93:405-409.
74. Lang K, Suttner S, Boldt J, et al. Volume replacement with HES 130=0.4 may reduce the inflammatory response in patients undergoing major abdominal surgery. Can J Anaesth 2003;50:1009-1016.
75. McKinley BA, Valdivia A, Moore FA. Goal-oriented shock resuscitation for major torso trauma: What are we learning? Curr Opin Crit Care 2003;9:292-299.
76. Boldt J, Ducke M, Kumle B, et al. Influence of different volume replacement strategies on inflammation and endothelial activation in the elderly undergoing major abdominal surgery. Intensive Care Med 2004;30:416-422.
77. Rhee P, Hadjizacharia P, Trankiem C, et al. What happened to total parenteral nutrition? The disappearance of its use in a trauma intensive care unit. J Trauma 2007;63:1215-1222.
78. Fong YM, Marano MA, Barber A, et al. Total parenteral nutrition and bowel rest modify the metabolic response to endotoxin in humans. Ann Surg 1989;210:449-456.
79. Lowry SF. The route of feeding influences injury responses. J Trauma 1990;30(12 Suppl):S10-S15.
80. Van Der Poll T, Levi M, Braxton CC, et al. Parenteral nutrition facilitates activation of coagulation but not of fibrinolysis during human endotoxemia. J Infect Dis 1998;177: 793-795.
81. Van Der Poll T, Coyle SM, Levi M, et al. Fat emulsion infusion potentiates coagulation activation during human endotoxemia. Thromb Haemost 1996;75:83-86.
82. Lowry SF.Anew model of nutrition influenced inflammatory risk. J Am Coll Surg 2007;205(4 Suppl):S65-S68.